In colitis-associated tumorigenesis, in contrast to WT mice, all CD68–mEPRAP transgenic mice survived the AOM/DSS treatment (Fig 5G), and CD68–mEPRAP transgenic mice developed fewer polyps (Fig 5H and 5I). This evidence concerns the gene CD68 and colitis.